Compare IPCA Labs with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs UNICHEM LAB - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS UNICHEM LAB IPCA LABS/
UNICHEM LAB
 
P/E (TTM) x 24.6 -44.5 - View Chart
P/BV x 8.8 1.1 803.6% View Chart
Dividend Yield % 0.1 1.3 10.9%  

Financials

 IPCA LABS   UNICHEM LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-19
UNICHEM LAB
Mar-19
IPCA LABS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,042292 356.8%   
Low Rs590182 324.2%   
Sales per share (Unadj.) Rs298.6167.7 178.1%  
Earnings per share (Unadj.) Rs35.0-3.6 -964.0%  
Cash flow per share (Unadj.) Rs49.45.9 832.1%  
Dividends per share (Unadj.) Rs3.004.00 75.0%  
Dividend yield (eoy) %0.41.7 21.8%  
Book value per share (Unadj.) Rs247.1372.3 66.4%  
Shares outstanding (eoy) m126.3570.38 179.5%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.71.4 193.3%   
Avg P/E ratio x23.3-65.3 -35.7%  
P/CF ratio (eoy) x16.539.9 41.4%  
Price / Book Value ratio x3.30.6 518.7%  
Dividend payout %8.6-110.2 -7.8%   
Avg Mkt Cap Rs m103,10816,680 618.2%   
No. of employees `00013.42.6 516.6%   
Total wages/salary Rs m7,8742,393 329.0%   
Avg. sales/employee Rs Th2,807.04,535.2 61.9%   
Avg. wages/employee Rs Th585.8919.8 63.7%   
Avg. net profit/employee Rs Th329.0-98.2 -335.0%   
INCOME DATA
Net Sales Rs m37,73211,801 319.7%  
Other income Rs m577984 58.6%   
Total revenues Rs m38,30912,785 299.6%   
Gross profit Rs m6,901-835 -826.5%  
Depreciation Rs m1,824674 270.8%   
Interest Rs m18975 250.9%   
Profit before tax Rs m5,465-600 -911.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042-343 -303.5%   
Profit after tax Rs m4,422-256 -1,730.6%  
Gross profit margin %18.3-7.1 -258.5%  
Effective tax rate %19.157.3 33.3%   
Net profit margin %11.7-2.2 -541.2%  
BALANCE SHEET DATA
Current assets Rs m23,77820,384 116.6%   
Current liabilities Rs m10,9755,029 218.2%   
Net working cap to sales %33.9130.1 26.1%  
Current ratio x2.24.1 53.5%  
Inventory Days Days104105 99.0%  
Debtors Days Days66135 48.9%  
Net fixed assets Rs m20,3689,023 225.7%   
Share capital Rs m253141 179.5%   
"Free" reserves Rs m30,97126,058 118.9%   
Net worth Rs m31,22426,199 119.2%   
Long term debt Rs m1,4090-   
Total assets Rs m45,50731,496 144.5%  
Interest coverage x30.0-7.0 -429.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.4 221.3%   
Return on assets %10.1-0.6 -1,769.7%  
Return on equity %14.2-1.0 -1,452.1%  
Return on capital %17.3-2.0 -866.5%  
Exports to sales %45.969.4 66.1%   
Imports to sales %16.60-   
Exports (fob) Rs m17,3088,188 211.4%   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3088,188 211.4%   
Fx outflow Rs m6,266596 1,051.4%   
Net fx Rs m11,0427,592 145.4%   
CASH FLOW
From Operations Rs m4,923-3,278 -150.2%  
From Investments Rs m-1,563-2,860 54.7%  
From Financial Activity Rs m-1,832-24 7,570.2%  
Net Cashflow Rs m1,528-4,690 -32.6%  

Share Holding

Indian Promoters % 45.9 50.1 91.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 15.1 75.5%  
FIIs % 25.3 3.0 843.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 31.7 54.9%  
Shareholders   36,892 20,176 182.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 19, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ORCHID PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS